 This was a Phase II, multicenter international, randomized, double-blind, placebo-controlled, parallel, dose-ranging study to evaluate the efficacy of multiple doses of an altered peptide ligand, NBI-6024, in adult 18 to 35 years of age and adolescent 10 to 17 years of age patients with new onset type 1 diabetes mellitus. 